The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positively contributes to the efficacy of cancer treatment. The only available therapeutics targeting PD-1/PD-L1 are monoclonal antibody-based drugs, which have several limitations.
View Article and Find Full Text PDFPurpose: The aim of the study was to evaluate association of apo E polymorphism with AMD.
Material And Methods: The included participants of this study were: 45 patients aged 60 to 71 (mean age 66.2 +/- 3.